20:49 , Apr 11, 2019 |  BC Week In Review  |  Clinical News

Cerevel's GABA A modulator reduces photosensitivity in epilepsy patients

After spinning out of Pfizer in October to develop the pharma's discontinued neuroscience pipeline, Cerevel plans to begin by year end another Phase II trial of CVL-865 in broader epilepsy populations. Cerevel Therapeutics LLC (Boston,...
21:43 , Oct 26, 2018 |  BioCentury  |  Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Mouse model of intellectual disability involving non-POU domain containing octamer-binding (NONO; NMT55) mutations

Disease models GABA A receptor GABRA2 gephyrin (GPHN) non-POU domain containing octamer-binding NMT55 University of Zurich...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models A mouse model of schizophrenia involving disruption of GABAA receptor clustering Mice with disrupted clustering of GABAA receptors could provide a...